Trial Profile
Observational, multicentre, ambispective study to assess long-term responders to first-line bevacizumab-based therapy in metastatic breast cancer (MBC) patients.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 02 Jun 2017
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary)
- Indications Advanced breast cancer; Breast cancer
- Focus Therapeutic Use
- Acronyms LORENA
- 02 Jun 2017 Results presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
- 02 Jun 2017 New trial record